Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Identifies New Mineralised Trends and Refines Targeting with Magnetic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Relief Therapeutics Ord Shs RLFTF

Healthcare Biotechnology
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of... see more

Recent & Breaking News (OTCQB:RLFTF)

Relief Therapeutics Announces Results of Annual General Meeting

ACCESS Newswire 1 day ago

Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

ACCESS Newswire May 22, 2025

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

ACCESS Newswire May 15, 2025

Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

ACCESS Newswire April 10, 2025

Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

ACCESS Newswire March 6, 2025

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

ACCESS Newswire February 11, 2025

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

ACCESS Newswire January 22, 2025

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

ACCESS Newswire December 27, 2024

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

ACCESS Newswire December 16, 2024

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

ACCESS Newswire December 13, 2024

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

ACCESS Newswire November 11, 2024

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

ACCESS Newswire November 4, 2024

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

ACCESS Newswire October 29, 2024

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

ACCESS Newswire October 25, 2024

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

ACCESS Newswire October 21, 2024

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

ACCESS Newswire October 8, 2024

Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

ACCESS Newswire October 4, 2024

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

ACCESS Newswire September 18, 2024

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

ACCESS Newswire September 2, 2024

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

ACCESS Newswire August 30, 2024